Outcome prediction with p53 immunostaining after radical prostatectomy in patients with locally advanced prostate cancer

Bradley C. Leibovich, Liang Cheng, Amy L. Weaver, Robert P. Myers, David G. Bostwick

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Purpose: Conventional pathological variables in prostate cancer may not provide optimal prediction of patient outcome. Pathological findings and p53 immunostaining were measured prospectively in radical prostatectomy specimens to determine the incremental improvement in prediction of patient outcome over clinical findings. Materials and Methods: From a previous prospective study of 392 consecutive patients with prostate cancer who did not receive preoperative therapy and were treated with radical prostatectomy 25 had pathological stage pT3aN0M0, 24 had pT3bN0M0, 2 had pT2bN1M0, 7 had pT3aN1M0 and 14 had pT3bN1 prostate cancer. These locally advanced stage cases comprise the current study population and further analysis was done with p53 immunostaining. All prostate specimens were totally embedded, serially sectioned and whole mounted. We examined pathological, clinical and laboratory findings as well as p53 immunostaining. Results: Median followup was 5.4 years (range 0.5 to 6.4). Univariate analysis revealed that pathological stage, 10% or greater immunostaining for p53, area and length of extraprostatic cancer extension, and cancer volume (all p ≤0.03) were associated with biochemical (prostate specific antigen) or clinical failure. When all variables were considered in stepwise multivariate analysis none attained statistical significance after p53 status entered the model (p

Original languageEnglish (US)
Pages (from-to)1756-1760
Number of pages5
JournalJournal of Urology
Volume163
Issue number6
StatePublished - Jun 2000
Externally publishedYes

Fingerprint

Prostatectomy
Prostatic Neoplasms
Prostate-Specific Antigen
Prostate
Neoplasms
Multivariate Analysis
Prospective Studies
Population
Therapeutics

Keywords

  • Prostate
  • Prostate-specific antigen
  • Prostatectomy
  • Prostatic neoplasms
  • Protein p53

ASJC Scopus subject areas

  • Urology

Cite this

Outcome prediction with p53 immunostaining after radical prostatectomy in patients with locally advanced prostate cancer. / Leibovich, Bradley C.; Cheng, Liang; Weaver, Amy L.; Myers, Robert P.; Bostwick, David G.

In: Journal of Urology, Vol. 163, No. 6, 06.2000, p. 1756-1760.

Research output: Contribution to journalArticle

Leibovich, Bradley C. ; Cheng, Liang ; Weaver, Amy L. ; Myers, Robert P. ; Bostwick, David G. / Outcome prediction with p53 immunostaining after radical prostatectomy in patients with locally advanced prostate cancer. In: Journal of Urology. 2000 ; Vol. 163, No. 6. pp. 1756-1760.
@article{3cd4207291844d27a341674ef7583110,
title = "Outcome prediction with p53 immunostaining after radical prostatectomy in patients with locally advanced prostate cancer",
abstract = "Purpose: Conventional pathological variables in prostate cancer may not provide optimal prediction of patient outcome. Pathological findings and p53 immunostaining were measured prospectively in radical prostatectomy specimens to determine the incremental improvement in prediction of patient outcome over clinical findings. Materials and Methods: From a previous prospective study of 392 consecutive patients with prostate cancer who did not receive preoperative therapy and were treated with radical prostatectomy 25 had pathological stage pT3aN0M0, 24 had pT3bN0M0, 2 had pT2bN1M0, 7 had pT3aN1M0 and 14 had pT3bN1 prostate cancer. These locally advanced stage cases comprise the current study population and further analysis was done with p53 immunostaining. All prostate specimens were totally embedded, serially sectioned and whole mounted. We examined pathological, clinical and laboratory findings as well as p53 immunostaining. Results: Median followup was 5.4 years (range 0.5 to 6.4). Univariate analysis revealed that pathological stage, 10{\%} or greater immunostaining for p53, area and length of extraprostatic cancer extension, and cancer volume (all p ≤0.03) were associated with biochemical (prostate specific antigen) or clinical failure. When all variables were considered in stepwise multivariate analysis none attained statistical significance after p53 status entered the model (p",
keywords = "Prostate, Prostate-specific antigen, Prostatectomy, Prostatic neoplasms, Protein p53",
author = "Leibovich, {Bradley C.} and Liang Cheng and Weaver, {Amy L.} and Myers, {Robert P.} and Bostwick, {David G.}",
year = "2000",
month = "6",
language = "English (US)",
volume = "163",
pages = "1756--1760",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Outcome prediction with p53 immunostaining after radical prostatectomy in patients with locally advanced prostate cancer

AU - Leibovich, Bradley C.

AU - Cheng, Liang

AU - Weaver, Amy L.

AU - Myers, Robert P.

AU - Bostwick, David G.

PY - 2000/6

Y1 - 2000/6

N2 - Purpose: Conventional pathological variables in prostate cancer may not provide optimal prediction of patient outcome. Pathological findings and p53 immunostaining were measured prospectively in radical prostatectomy specimens to determine the incremental improvement in prediction of patient outcome over clinical findings. Materials and Methods: From a previous prospective study of 392 consecutive patients with prostate cancer who did not receive preoperative therapy and were treated with radical prostatectomy 25 had pathological stage pT3aN0M0, 24 had pT3bN0M0, 2 had pT2bN1M0, 7 had pT3aN1M0 and 14 had pT3bN1 prostate cancer. These locally advanced stage cases comprise the current study population and further analysis was done with p53 immunostaining. All prostate specimens were totally embedded, serially sectioned and whole mounted. We examined pathological, clinical and laboratory findings as well as p53 immunostaining. Results: Median followup was 5.4 years (range 0.5 to 6.4). Univariate analysis revealed that pathological stage, 10% or greater immunostaining for p53, area and length of extraprostatic cancer extension, and cancer volume (all p ≤0.03) were associated with biochemical (prostate specific antigen) or clinical failure. When all variables were considered in stepwise multivariate analysis none attained statistical significance after p53 status entered the model (p

AB - Purpose: Conventional pathological variables in prostate cancer may not provide optimal prediction of patient outcome. Pathological findings and p53 immunostaining were measured prospectively in radical prostatectomy specimens to determine the incremental improvement in prediction of patient outcome over clinical findings. Materials and Methods: From a previous prospective study of 392 consecutive patients with prostate cancer who did not receive preoperative therapy and were treated with radical prostatectomy 25 had pathological stage pT3aN0M0, 24 had pT3bN0M0, 2 had pT2bN1M0, 7 had pT3aN1M0 and 14 had pT3bN1 prostate cancer. These locally advanced stage cases comprise the current study population and further analysis was done with p53 immunostaining. All prostate specimens were totally embedded, serially sectioned and whole mounted. We examined pathological, clinical and laboratory findings as well as p53 immunostaining. Results: Median followup was 5.4 years (range 0.5 to 6.4). Univariate analysis revealed that pathological stage, 10% or greater immunostaining for p53, area and length of extraprostatic cancer extension, and cancer volume (all p ≤0.03) were associated with biochemical (prostate specific antigen) or clinical failure. When all variables were considered in stepwise multivariate analysis none attained statistical significance after p53 status entered the model (p

KW - Prostate

KW - Prostate-specific antigen

KW - Prostatectomy

KW - Prostatic neoplasms

KW - Protein p53

UR - http://www.scopus.com/inward/record.url?scp=0034045170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034045170&partnerID=8YFLogxK

M3 - Article

VL - 163

SP - 1756

EP - 1760

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 6

ER -